Immunosuppressant strategies for intestinal transplantation: A review of a tolerogenic regimen

Progress in Transplantation

Volumn 15, Issue 1, 2005, Pages 60-64

  Flynn, Bridget ^a   Park, Beverly Kosmach ^a   Bond, Geoffrey ^a   McGhee, William ^a   Mazariegos, George ^a   Sindhi, Rakesh ^a   Reyes, Jorge ^b   Abu Elmagd, Kareem ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; CYCLOPHOSPHAMIDE; DACLIZUMAB; INTERLEUKIN 2; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PROSTAGLANDIN E1; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; IMMUNOSUPPRESSIVE AGENT;

CROHN DISEASE; DISEASE COURSE; DISEASE SEVERITY; DONOR SELECTION; GASTROSCHISIS; GRAFT INFECTION; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INTESTINAL DYSMOTILITY; INTESTINE ATRESIA; INTESTINE ISCHEMIA; INTESTINE TRANSPLANTATION; IRRADIATION; LYMPHOCYTE DEPLETION; MONOTHERAPY; NECROTIZING ENTEROCOLITIS; OUTCOME ASSESSMENT; POSTOPERATIVE CARE; QUALITY OF LIFE; RADIATION DOSE; REVIEW; RISK FACTOR; SURGICAL TECHNIQUE; SURVIVAL RATE; SURVIVAL TIME; TREATMENT INDICATION; VOLVULUS; INTESTINE; METHODOLOGY; TRANSPLANTATION;

GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INTESTINES; SURVIVAL RATE;

EID: 19844368958     PISSN: 15269248     EISSN: None     Source Type: Journal    
DOI: 10.7182/prtr.15.1.c43t80h754715g32     Document Type: Review

References (22)

1. Grant D, Abu-Elmagd K, Reyes J, et al. Report of the intestine transplant registry: a new era has dawned. Ann Surg. In press.
2. Grant D. Intestinal transplantation: 2003 report of the international intestinal transplant registry. Available at: http://www.lhsc.on.ca/itr. Accessed July 1, 2004.
3. Bond G, Costa G, Mazariegos G, et al. Intestinal Failure and Visceral Transplantation: A New Era of Colossal Achievement. Boca Ratan, Fla: CRC Press; 2004.
4. Abu-Elmagd K, Reyes J, Bond G, et al. Clinical intestinal transplantation: a decade of experience at a single center. Ann Surg. 2004;234:404-417.
5. Abu-Elmagd K, Reyes J, Todo S, et al. Clinical intestinal transplantation: new perspectives and immunologic considerations. J Am Coll Sur. 1998;186:512-527.
6. Todo S, Reyes J, Furukawa H, et al. Outcome analysis of 71 clinical intestinal transplantations. Ann Surg. 1995;222:270-282.
7. Abu-Elmagd K, Fung J, McGhee W, et al. The efficacy of daclizumab for intestinal transplantation: preliminary report. Transplant Proc. 2000;32:1195-1196.
8. Starzl TE, Murase N, Abu-Elmagd K, et al. Tolerogenic immunosuppression for organ transplantation. Lancet. 2003; 361:1502-1510.
9. Murase N, Starzl TE, Tanabe M, et al. Variable chimerism, graft-versus-host disease, and tolerance after different kinds of cell and whole organ transplantation from Lewis to Brown Norway rats. Transplantation. 1995;60:158-171.
10. Murase N, Ye Q, Nalesnik MA, et al. Immunomodulation for intestinal transplantation by allograft irradiation, adjunct donor bone marrow infusion, or both. Transplantation. 2000;70:1632-1641.
11. Starzl TE, Demetris AJ, Murase N, et al. Cell migration, chimerism, and graft acceptance. Lancet. 1992;339:1579-1582.
12. Starzl TE, Zinkemagel R. Antigen localization and migration in immunity and tolerance. N Engl J Med. 1998;339:1905-1913.
13. Thymoglobulin® Anti-thymocyte Globulin (Rabbit) [prescribing information]. Fremont, Calif: Sangstat Medical Corporation; 2002.
14. Bond G, Reyes JR, Mazariegos GM. Pediatric intestinal transplantation at Children's Hospital of Pittsburgh. Paper presented at: VII International Small Bowel Transplant Symposium; September 10-13, 2003; Bal Harbour, Fla.
15. Campath® (Alemtuzumab) [prescribing information]. Richmond, Calif: Berlex Laboratories; 2002.
16. Abu-Elmagd K, Todo S, Tzakis A, et al. Three years clinical experience with intestinal transplantation. J Am Coll Surg. 1994;179:385-400.
17. Abu-Elmagd K, Fung JJ, Reyes J, et al. Management of intestinal transplantation in humans. Transplant Proc. 1992;24: 1243-1244.
18. Parizhskaya M, Redondo C, Demetris A, et al. Chronic rejection of small bowel grafts: a pediatric and adult study of risk factors and morphologic progression. Ped Dev Path. 2003; 6:240-250.
19. Kato T, O'Brien CB, Berho M, et al. Improved rejection surveillance in intestinal transplant recipients with frequent use of zoom video endoscopy. Transplant Proc. 2000;32:1200.
20. Pappas PA, Saudubray JM, Tzakis AG, et al. Serum citrulline and rejection in small bowel transplantation: a preliminary report. Transplantation. 2001;72:1212-1216.
21. Starzl TE, Zinkernagel RM, Transplantation tolerance from an historical perspecitve. Nature Rev Immunol. 2001;1:233-239.
22. Starzl TE, Murase N, Demetris AJ, et al. Lessons of organ-induced tolerance learned from historical clinical experience. Transplantation. 2004;779:926-929.